Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Otezla (apremilast by Year

Name: Amgen Otezla (apremilast by Year (AMGN)
Creator: Amgen

Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide product sales ($M) ($M)

Quarterly Annual

Amgen Otezla (apremilast: $2,265M in FY2025, up 6.5% from a year earlier.

Latest, FY2025

2,265

Period ended Dec 31, 2025

Change on a year earlier

+6.5%

2,126 in FY2024

History

8 years

Since FY2018

Sources

Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide product sales ($M) ($M)	Year on year	Source
FY2025	Dec 31, 2025	2,265	+6.5%	Form 10-K (filed 2026-02-13) ↗
FY2024	Dec 31, 2024	2,126	-2.8%	Form 10-K (filed 2026-02-13) ↗
FY2023	Dec 31, 2023	2,188	-4.4%	Form 10-K (filed 2026-02-13) ↗
FY2022	Dec 31, 2022	2,288	+1.7%	Form 10-K (filed 2025-02-14) ↗
FY2021	Dec 31, 2021	2,249	+2.5%	Form 10-K (filed 2024-02-14) ↗
FY2020	Dec 31, 2020	2,195	+1,133.1%	Form 10-K (filed 2023-02-09) ↗
FY2019	Dec 31, 2019	178	–	Form 10-K (filed 2022-02-16) ↗
FY2018	Dec 31, 2018	0	–	Form 10-K (filed 2021-02-09) ↗

Breakdown

What makes up otezla (apremilast

Cite this data

StockData. (2026). Amgen Otezla (apremilast ($M), annual FY2018–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-otezla-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.